For more information on cannabis and Parkinson’s please visit the EPDA website.
The future of Parkinson’s and medicinal plants
Author: Simge Eva DoganPublished: 28 February 2019
Prep: Cook: Serves:
The Parkinson’s Foundation will be hosting its first Parkinson’s and medical marijuana conference to address the potential health benefits and risks of the drug. We spoke to Beth Vernaleo, Director of Research Programmes at the Parkinson’s Foundation, to find out what the conference hopes to achieve
The Parkinson’s and medical marijuana conference next month aims to establish a consensus statement on the clinical implications of using medical marijuana to treat symptoms of Parkinson’s.
Beth Vernaleo, Director of Research Programmes at the Parkinson’s Foundation – which is behind the conference in Denver, US, on 6-7 March – says:
“I help to organise convenings on various topics that are identified by the Parkinson’s community as an unmet need. We realised that medical marijuana is something that patients are asking about all the time – and there’s not a lot known about it.”
Attendees will include experts and advocates from the Parkinson’s community, academia, government, industry and clinics. Beth says: “We’ve invited a diverse group of stakeholders to cover a wide range of things. We’re looking to the few studies that have been done to see what the effects for symptomatic and neuroprotective benefits are.
“There are many different strains of cannabis and there are many different ways of delivering it – such as smoking or oils. We want to discuss the possible ways to deliver different formulations and what might be most beneficial.”
Bringing together Parkinson’s experts, the conference will also outline areas for more clinical research.
“We don’t know if we’re ready for a clinical trial yet or if we still need further research,” explains Beth. “So we’re also inviting people who have experience in clinical trial design to help decide what would be the best way to create a vigorous clinical trial.”
As well as establishing a consensus to guide the Parkinson’s community on medical marijuana use, the conference also hopes to further research in this field.
“Based on research questions that come out of the meeting, we would like to put together funding for cannabis-based research in Parkinson’s. We were thinking of five projects that are a year-long that we could fund at USD $100,000 each.”
Discussing the current attitudes towards medical marijuana in the Parkinson’s community, Beth says: “Many people are very interested in it, many people have tried it already. I think people are equating access with efficacy – and that’s just not the case. That’s why we want to have this meeting.”
The Parkinson’s Foundation will publish areas for further research and guidance on Parkinson’s and medical marijuana use following the conference. To find out more about the conference click here.
Share this story
How DBS can help improve Parkinson’s mobility issues
Learn about the ACTIVA™ RC Neurostimulator from MedtronicREAD MORE
Hitting the sweet spot: how the new directional DBS system improves symptom control in Parkinson’s disease
New tech can find the brain’s ‘sweet spot’ for improved effectivenessREAD MORE
These photos could change the way the world sees Parkinson’s forever
The photographer who's giving Parkinson's a 'total makeover'READ MORE